Sign In
Buy EYPT
$13.73
+0.150 (+1.10%)
At Close: Jun 22, 2026
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Tuesday, 16'th Jun 2026
WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
05:12pm, Tuesday, 09'th Jun 2026
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
12:05pm, Tuesday, 26'th May 2026
Eyepoint Pharmaceuticals NASDAQ: EYPT executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-
EyePoint Announces Participation at Upcoming Investor Conferences
07:00am, Tuesday, 19'th May 2026
WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with se
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Monday, 18'th May 2026
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four pre
EyePoint: DURAVYU's Durability Could Drive Significant Upside
01:58am, Thursday, 14'th May 2026
EyePoint is rated a clear BUY, with central-case DCF modeling indicating roughly 2x upside from current levels. DURAVYU, EYPT's lead candidate for wet AMD and DME, has demonstrated a compelling durabi
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
05:51pm, Wednesday, 06'th May 2026
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates
09:25am, Wednesday, 06'th May 2026
EyePoint (EYPT) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.65 per share a year ago.
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
07:00am, Wednesday, 06'th May 2026
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with se
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
07:00am, Wednesday, 29'th Apr 2026
WATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Ramiro Ribeiro Sells 2,437 Shares of Stock
04:57am, Tuesday, 21'st Apr 2026
Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction on Friday, April 17th. The shares were sold
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Thursday, 16'th Apr 2026
WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with seriou
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT
03:07am, Monday, 06'th Apr 2026
Aberdeen Group plc boosted its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) by 101.6% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commis
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference
01:32am, Friday, 27'th Mar 2026
Executives from Eyepoint Pharmaceuticals (NASDAQ: EYPT) told investors at RBC Capital Markets' Ophthalmology Conference that the company's lead program, DURAVYU (vorolanib), is advancing through four
